tetano
Editor, Senior Moderator
Biomed Pharmacother
. 2020 Jul 28;130:110529.
doi: 10.1016/j.biopha.2020.110529. Online ahead of print.
Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience
Yan Hu[SUP] 1 [/SUP], Tingping Wang[SUP] 1 [/SUP], Zhimin Hu[SUP] 1 [/SUP], Xuan Wang[SUP] 1 [/SUP], Zhengbin Zhang[SUP] 1 [/SUP], Li Li[SUP] 2 [/SUP], Peng Peng[SUP] 3 [/SUP]
Affiliations
Abstract
The aim of the present study was to identify the clinical efficacy of glucocorticoid therapy on the treatment of patients with Coronavirus Disease 2019 (COVID-19) pneumonia. Clinical and laboratory parameters were collected from 308 patients with COVID-19 pneumonia from the fever clinic of Wuhan Pulmonary Hospital (Wuhan City, Hubei Province, China) between January 14, 2020 and February 9, 2020, of which 216 patients received low-dose (equivalent of methylprednisolone 0.75-1.5 mg/kg/d) glucocorticoid treatment. The effect of glucocorticoid on imaging progress, adverse events, nucleic acid results and the outcomes were investigated. Lymphocyte count and C-reactive protein (CRP) significantly differed between the glucocorticoid therapy and non-glucocorticoid therapy groups. Compared with the non-glucocorticoid therapy group, glucocorticoid therapy did not significantly influence the clinical course of COVID-19 pneumonia, including imaging progress and the time duration for negative transformation of nucleic acid. Glucocorticoid therapy did not significantly influence the outcomes nor the adverse events of COVID-19 pneumonia. For the treatment of COVID-19 pneumonia, systemic and in-depth investigation is needed to determine the timing and dosage of glucocorticoids needed to inhibit overwhelming inflammatory response and not the protective immune response to COVID-19 pneumonia.
Keywords: COVID-19; Clinical course; Glucocorticoid therapy.
. 2020 Jul 28;130:110529.
doi: 10.1016/j.biopha.2020.110529. Online ahead of print.
Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience
Yan Hu[SUP] 1 [/SUP], Tingping Wang[SUP] 1 [/SUP], Zhimin Hu[SUP] 1 [/SUP], Xuan Wang[SUP] 1 [/SUP], Zhengbin Zhang[SUP] 1 [/SUP], Li Li[SUP] 2 [/SUP], Peng Peng[SUP] 3 [/SUP]
Affiliations
- PMID: 32736237
- DOI: 10.1016/j.biopha.2020.110529
Abstract
The aim of the present study was to identify the clinical efficacy of glucocorticoid therapy on the treatment of patients with Coronavirus Disease 2019 (COVID-19) pneumonia. Clinical and laboratory parameters were collected from 308 patients with COVID-19 pneumonia from the fever clinic of Wuhan Pulmonary Hospital (Wuhan City, Hubei Province, China) between January 14, 2020 and February 9, 2020, of which 216 patients received low-dose (equivalent of methylprednisolone 0.75-1.5 mg/kg/d) glucocorticoid treatment. The effect of glucocorticoid on imaging progress, adverse events, nucleic acid results and the outcomes were investigated. Lymphocyte count and C-reactive protein (CRP) significantly differed between the glucocorticoid therapy and non-glucocorticoid therapy groups. Compared with the non-glucocorticoid therapy group, glucocorticoid therapy did not significantly influence the clinical course of COVID-19 pneumonia, including imaging progress and the time duration for negative transformation of nucleic acid. Glucocorticoid therapy did not significantly influence the outcomes nor the adverse events of COVID-19 pneumonia. For the treatment of COVID-19 pneumonia, systemic and in-depth investigation is needed to determine the timing and dosage of glucocorticoids needed to inhibit overwhelming inflammatory response and not the protective immune response to COVID-19 pneumonia.
Keywords: COVID-19; Clinical course; Glucocorticoid therapy.